Charles Schwab Investment Management Inc. Grows Stock Holdings in Disc Medicine, Inc. $IRON

Key Points

• Charles Schwab Investment Management Inc. raised its holdings in Disc Medicine, Inc. by 18.0% in Q1, owning approximately 0.56% of the company, valued at $9.67 million.
• Disc Medicine reported a quarterly EPS of (1.58), missing analysts' expectations of (1.17), with analysts projecting a full fiscal year EPS of (4.07).
• Institutional investors control 83.70% of Disc Medicine's stock, highlighting strong investor confidence and interest in the company.

Charles Schwab Investment Management Inc. lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 18.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 194,725 shares of the company's stock after acquiring an additional 29,653 shares during the period. Charles Schwab Investment Management Inc. owned 0.56% of Disc Medicine worth $9,666,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IRON. Price T Rowe Associates Inc. MD grew its position in Disc Medicine by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company's stock worth $88,421,000 after purchasing an additional 262,690 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Disc Medicine by 22.2% in the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company's stock valued at $64,782,000 after buying an additional 236,800 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Disc Medicine by 62.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company's stock worth $77,170,000 after buying an additional 467,988 shares during the period. Woodline Partners LP grew its holdings in shares of Disc Medicine by 5.2% during the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company's stock worth $25,144,000 after buying an additional 19,538 shares during the last quarter. Finally, MPM Bioimpact LLC increased its position in Disc Medicine by 11.1% in the 4th quarter. MPM Bioimpact LLC now owns 346,401 shares of the company's stock valued at $21,962,000 after acquiring an additional 34,640 shares during the period. Hedge funds and other institutional investors own 83.70% of the company's stock.

Disc Medicine Price Performance

Shares of IRON traded down $0.01 during mid-day trading on Friday, reaching $59.65. 214,790 shares of the company's stock were exchanged, compared to its average volume of 395,650. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $68.73. The company has a quick ratio of 32.11, a current ratio of 32.11 and a debt-to-equity ratio of 0.05. The company has a 50-day simple moving average of $57.60 and a two-hundred day simple moving average of $51.80. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -13.34 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.41). On average, sell-side analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on IRON shares. Truist Financial began coverage on Disc Medicine in a research note on Monday, July 21st. They issued a "buy" rating and a $86.00 target price on the stock. Wedbush reiterated an "outperform" rating and issued a $90.00 price objective on shares of Disc Medicine in a research report on Monday, July 21st. HC Wainwright reissued a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Thursday, July 3rd. Raymond James Financial initiated coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 target price for the company. Finally, BMO Capital Markets lifted their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $98.30.

Insider Activity

In other Disc Medicine news, insider William Jacob Savage sold 2,996 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $50.00, for a total value of $149,800.00. Following the transaction, the insider directly owned 56,725 shares in the company, valued at approximately $2,836,250. This represents a 5.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John D. Quisel sold 34,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $55.33, for a total transaction of $1,925,484.00. Following the sale, the chief executive officer owned 161,828 shares in the company, valued at approximately $8,953,943.24. This trade represents a 17.70% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 135,909 shares of company stock worth $8,006,371. Company insiders own 3.64% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.